3728-20-9

Basic information

• Product Name: H-D-TYR-OME HCL
• Synonyms: (R)-Methyl 2-aMino-3-(4-hydroxyphenyl)propanoate hydrochloride;H-D-Tyr-OMe hydrochloride;H-D-Tyr-OMe;D-Tyr-OMe·HCl;D-Tyrosine methyl ester hydrochloride≥ 98% (HPLC);D-TYROSINE ETHYL OME HCl;Methyl D-Tyrosinate Hydrochloride,99%e.e.;H-D-TYR-OME HCL
• CAS NO: 3728-20-9
• Molecular Formula: C₁₀H₁₄NO₃*Cl
• Molecular Weight: 231.68
• EINECS: 223-084-2
• Product Categories: Amino Acids and Derivatives;Amino hydrochloride;Amino Acid Derivatives
• Mol File: 3728-20-9.mol
• Article Data: 39

Chemical Properties

• Melting Point: 177-179℃
• Boiling Point: 330 °C at 760 mmHg
• Flash Point: 153.4 °C
• Appearance: White to off-white/Powder
• Vapor Pressure: 8.89E-05mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: H-D-TYR-OME HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-TYR-OME HCL(3728-20-9)
• EPA Substance Registry System: H-D-TYR-OME HCL(3728-20-9)

Safety Data

• Hazardous Substances Data: 3728-20-9(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline

Uses

D-Tyrosine methyl ester hydrochloride is an intermediate in the synthesis of oxybutynin chloride (O868525), an inhibitor of proliferation and supresses gene expression in bladder smooth muscle cells.

InChI:InChI=1/C10H13NO3.ClH/c1-14-10(13)9(11)6-7-2-4-8(12)5-3-7;/h2-5,9,12H,6,11H2,1H3;1H/t9-;/m1./s1

Upstream product

• 556-02-5 tyrosine 
• 67-56-1 methanol 
• 60-18-4 L-tyrosine 
• 3417-91-2 tyrosine methyl ester hydrochloride 
• 142847-18-5 N-(tert-butoxycarbonyl)tyrosine 
• 556-02-5 ?Tyr 

Downstream Products

• 86965-70-0 β-benzylthiopropionyl-D-tyrosine hydrazide 
• 22838-84-2 N-(benzyloxycarbonyl)-β-benzyl-L-aspartyl-D-tyrosine methyl ester 
• 145401-85-0 (R)-α-methylbenzylcarbamoyl-D-tyrosine methyl ester 
• 144862-92-0 (R)-2-(6-Chloro-2-methoxy-acridin-9-ylamino)-3-(4-hydroxy-phenyl)-propionic acid methyl ester; hydrochloride 
• 851588-98-2 (R)-3-(4-Hydroxy-phenyl)-2-((Z)-octadec-9-enoylamino)-propionic acid methyl ester 
• 22221-58-5 2-decanoylamino-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 935548-01-9 {3-eicosanoylamino-4-[4-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethoxy)-phenyl]-2-oxo-butyl}-phosphonic acid dimethyl ester 
• 935548-00-8 {4-[4-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethoxy)-phenyl]-3-octadecanoylamino-2-oxo-butyl}-phosphonic acid dimethyl ester 
• 65160-71-6 methyl (2R)-2-acetamido-3-(4-hydroxyphenyl)propanoate 
• 935548-31-5 (3-hexadecanoylamino-2-oxo-4-{4-[4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethoxy]-phenyl}-butyl)-phosphonic acid dimethyl ester 
• 935548-02-0 {4-[4-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethoxy)-phenyl]-3-octadec-9-enoylamino-2-oxo-butyl}-phosphonic acid dimethyl ester 

Relevant articles and documents

(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative as well as preparation method and application thereof

The invention discloses a (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative shown as a formula (I) or an optical isomer, a diastereomer and racemate mixture and pharmaceutically acceptable salt thereof as well as a preparation method and application of the (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative. It is shown by comparison of results of a positive control group and a model group on lymphedema prevention experiments that the compound disclosed in the invention shows obvious anti-edema activity.

NovelN-transfer reagent for converting α-amino acid derivatives to α-diazo compounds

A novel universalN-transfer reagent for direct and effective transformation of α-amino ketones, acetamides, and esters to the corresponding α-diazo products under mild basic conditions has been developed. This one-step synthetic approach not only allows for generation of α-substituted-α-diazo carbonyl compounds from α-amino acid derivatives but also permits preparation of α-diazo dipeptides fromN-terminal dipeptides (32 examples, up to 91%).

Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors

The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Aberrant activation by a wide range of exogenous and endogenous signals can lead to chronic, low-grade inflammation. It has attracted a great deal of interest as a drug target due to the association with diseases of large unmet medical need such as Alzheimer's disease, Parkinson's disease, arthritis, and cancer. To date, no drugs specifically targeting inhibition of the NLRP3 inflammasome have been approved. In this work, we used the known NLRP3 inflammasome inhibitor CP-456,773 (aka CRID3 or MCC 950) as our starting point and undertook a Structure-Activity Relationship (SAR) analysis and subsequent scaffold-hopping exercise. This resulted in the rational design of a series of novel ester-substituted urea compounds that are highly potent and selective NLRP3 inflammasome inhibitors, as exemplified by compounds 44 and 45. It is hypothesized that the ester moiety acts as a highly permeable delivery vehicle and is subsequently hydrolyzed to the carboxylic acid active species by carboxylesterase enzymes. These molecules are greatly differentiated from the state-of-the-art and offer potential in the treatment of NLRP3-driven diseases, particularly where tissue penetration is required.